We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Modified Nanoparticle Drug Carriers Target Solid Tumors in Model

By LabMedica International staff writers
Posted on 27 Nov 2018
Cancer researchers used novel targeted nanoparticles to transport drugs to solid tumors when the absence of a persistent EPR (enhanced permeability and retention) effect, acted as an access barrier negatively affected the effectiveness of drug delivery.

The EPR effect is a controversial concept by which molecules of certain sizes (typically liposomes, nanoparticles, and macromolecular drugs) tend to accumulate in tumor tissue much more than they do in normal tissues. More...
The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels. Tumor cell aggregates as small as 150–200 micrometers, start to become dependent on blood supply carried out by newly formed blood vessels for their nutritional and oxygen supply. These newly formed tumor vessels are usually abnormal in form and architecture. Furthermore, tumor tissues usually lack effective lymphatic drainage. All of these factors lead to abnormal molecular and fluid transport dynamics, especially for macromolecular drugs. This phenomenon is referred to as the "enhanced permeability and retention (EPR) effect" of macromolecules and lipids in solid tumors.

Investigators at Purdue University (West Lafayette, IN, USA) looked at the situation in which the absence of a persistent EPR effect functioned as an access barrier to tumors and negatively affected the effectiveness of nanoparticle (NP) drug carriers.

They reported in the November 9, 2018, online edition of the journal Small that when NPs were modified with a quinic acid (QA) derivative, they acted as synthetic mimics of selectin ligands. Selectins are a family of cellular adhesion molecules involved in constitutive lymphocyte homing, and in chronic and acute inflammation processes, including post-ischemic inflammation in muscle, kidney and heart, skin inflammation, atherosclerosis, glomerulonephritis, lupus erythematosus, and cancer metastasis.

The investigators found that QA‐decorated NPs (QA‐NP) interacted with human umbilical vein endothelial cells expressing E‐/P‐selectins and induced a transient increase in endothelial permeability to translocate across the layer. QA‐NP reached selectin‐upregulated tumors, achieving greater tumor accumulation and paclitaxel (PTX) delivery than polyethylene glycol‐decorated NPs (PEG‐NP).

Repeated dosing of PTX‐loaded QA‐NP for two weeks resulted in complete tumor remission in 40–60% of MDA‐MB‐231 tumor‐bearing mice, while those receiving control treatments died from the tumors.

"Chemotherapy can be almost unbearable for most patients and we want to change that. Our method better targets tumors so lower dosages are required and the drugs do less damage to normal tissues," said senior author Dr. Yoon Yeo, professor of industrial and physical pharmacy at Purdue University. "The traditional approach is similar to a delivery driver trying to drop off a package to a certain person without knowing their specific address. Our new approach provides directions to find the specific address to deliver the chemotherapeutic drugs."

Related Links:
Purdue University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.